HomeKRONOX › Filing
🔔 Get instant alerts when KRONOX files quarterly results on BSE Start free trial →

Promoters informed the Company about the SPA executed by them with Indo Borax & Chemicals Limited (Acquirer) and Zenrock Chemicals Private Limited (PAC)

Filed: 20 Aug 2026, 13:18 IST Exchange: BSE Category: Merger/Acquisition — Share Purchase Agreement
Promoters executed SPA to sell 64.26% stake (2,38,44,000 shares) to Indo Borax & Chemicals Limited and Zenrock Chemicals Private Limited on Aug 20, 2026. - Acquirer and PAC to make mandatory tender offer per SEBI Takeover Regulations. - SPA price per share: Rs 103.22; effective price including consultancy fees Rs 105.87. - Sellers to cease promoter status; Acquirer and PAC to become promoter and promoter group. - Acquirer to appoint 3 nominee directors; Sellers to resign from board. - Sellers' remaining 9.95% shares locked-in; Acquirer has right of first refusal post lock-in. - Sellers to enter consultancy agreement post-transaction. - Completion subject to conditions precedent and regulatory approvals.
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 KRONOX — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add KRONOX to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Kronox Lab Sciences Limited

Important. The summary above is generated automatically from Kronox Lab Sciences Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.